ProMIS Neurosciences Inc. Announces 2024 Annual Meeting of Shareholders

Ticker: PMN · Form: DEF 14A · Filed: 2024-04-25T00:00:00.000Z

Sentiment: neutral

Topics: Proxy Statement, Annual Meeting, Shareholder Vote, Director Election, Auditor Ratification

TL;DR

<b>ProMIS Neurosciences Inc. will hold its 2024 virtual Annual Meeting on June 13, 2024, for shareholders of record as of April 15, 2024.</b>

AI Summary

ProMIS Neurosciences Inc. (PMN) filed a Proxy Statement (DEF 14A) with the SEC on April 25, 2024. The 2024 Annual Meeting of Shareholders for ProMIS Neurosciences Inc. will be held virtually on June 13, 2024, at 10:00 a.m. Eastern Time. Shareholders of record as of April 15, 2024, are eligible to vote at the meeting. Key agenda items include the election of seven directors, a special resolution regarding director numbers, and ratification of Baker Tilly US, LLP as the independent auditor for fiscal year 2024. The meeting will be conducted via live webcast, allowing for electronic voting and question submission. ProMIS Neurosciences Inc. was formerly known as AMORFIX LIFE SCIENCES LTD, with a name change effective August 31, 2006.

Why It Matters

For investors and stakeholders tracking ProMIS Neurosciences Inc., this filing contains several important signals. This filing is a proxy statement (DEF 14A) detailing the agenda and procedures for the upcoming shareholder meeting, which is crucial for corporate governance and decision-making. The matters to be voted on, such as director elections and auditor ratification, directly impact the company's leadership, financial oversight, and strategic direction.

Risk Assessment

Risk Level: low — ProMIS Neurosciences Inc. shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting and does not contain new financial or operational data that would indicate significant risk.

Analyst Insight

Shareholders should review the proxy materials to make informed voting decisions on director elections and other corporate matters at the June 13, 2024 meeting.

Key Numbers

Key Players & Entities

FAQ

When did ProMIS Neurosciences Inc. file this DEF 14A?

ProMIS Neurosciences Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 25, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by ProMIS Neurosciences Inc. (PMN).

Where can I read the original DEF 14A filing from ProMIS Neurosciences Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by ProMIS Neurosciences Inc..

What are the key takeaways from ProMIS Neurosciences Inc.'s DEF 14A?

ProMIS Neurosciences Inc. filed this DEF 14A on April 25, 2024. Key takeaways: The 2024 Annual Meeting of Shareholders for ProMIS Neurosciences Inc. will be held virtually on June 13, 2024, at 10:00 a.m. Eastern Time.. Shareholders of record as of April 15, 2024, are eligible to vote at the meeting.. Key agenda items include the election of seven directors, a special resolution regarding director numbers, and ratification of Baker Tilly US, LLP as the independent auditor for fiscal year 2024..

Is ProMIS Neurosciences Inc. a risky investment based on this filing?

Based on this DEF 14A, ProMIS Neurosciences Inc. presents a relatively low-risk profile. The filing is a routine proxy statement for an annual meeting and does not contain new financial or operational data that would indicate significant risk.

What should investors do after reading ProMIS Neurosciences Inc.'s DEF 14A?

Shareholders should review the proxy materials to make informed voting decisions on director elections and other corporate matters at the June 13, 2024 meeting. The overall sentiment from this filing is neutral.

Risk Factors

Key Dates

Filing Stats: 4,868 words · 19 min read · ~16 pages · Grade level 11.7 · Accepted 2024-04-25 16:30:16

Filing Documents

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 33 AUDIT COMMITTEE REPORT 39 PROPOSAL 3 RATIFICATION OF THE APPOINTMENT OF OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 40 PROPOSAL 4 ORDINARY RESOLUTION APPROVING THE UNALLOCATED STOCK OPTIONS UNDER THE STOCK OPTION PLAN 42 OTHER INFORMATION 45 i Table of Contents SUITE 200, 1920 YONGE STREET TORONTO, ONTARIO, CANADA M4S 3E2 (416) 847-6898 PROXY STATEMENT 2024 ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS To Be Held on June 13, 2024 This proxy statement contains information about the 2024 Annual Meeting of Shareholders of ProMIS Neurosciences Inc. (the "Annual Meeting"), to be held on Thursday, June 13, 2024 at 10:00 a.m., Eastern Time. This year's Annual Meeting will be a virtual meeting, which will be conducted via live webcast. In order to attend the Annual Meeting, you must register at www.virtualshareholdermeeting.com/PMN2024. Upon completing your registration, you will receive further instructions via email, including a unique link that will allow you access to the Annual Meeting and to vote and submit questions during the Annual Meeting. There will not be a physical meeting location, and shareholders will not be able to attend the Annual Meeting in person. Further information about how to attend the Annual Meeting online is included in this proxy statement below. Except where the context otherwise requires, references to "ProMIS Neurosciences," "ProMIS," "company," "we," "us," "our" and similar terms refer to ProMIS Neurosciences Inc. and its consolidated subsidiaries. This proxy statement summarizes information about the proposals to be considered at the meeting and other information you may find useful in determining how to vote. We are making this proxy statement, the related proxy card and our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the "2023 Annual Report"), available to shareholders for the first time on or about April 25, 2024. Pursuant to rules adopted by the S

View on Read The Filing